awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432F
Q34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432F
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
P2860
Q34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
21b05911c495043580179e4a6bfa7859c4a847fa
P2860
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.